Last reviewed · How we verify
JMT601
At a glance
| Generic name | JMT601 |
|---|---|
| Sponsor | Shanghai JMT-Bio Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy (PHASE2)
- Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma (PHASE1, PHASE2)
- A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMT601 CI brief — competitive landscape report
- JMT601 updates RSS · CI watch RSS
- Shanghai JMT-Bio Inc. portfolio CI